| Private Placement / Financing Transactions
Treeline Biosciences: The company raised $621.8 million of Series A venture funding in a deal led by Andreessen Horowitz on September 1, 2025. GV, Fidelity, Exor, OrbiMed, Kohlberg Kravis Roberts, ARCH Venture Partners, Arc Ventures, Ajax Health, Casdin Capital, Aisling Capital, Access Industries, Rock Springs Capital, and other undisclosed investors also participated in the round. The company is a developer of precision medicines intended to treat cancer and other serious conditions.
Enveda: The company raised $150 million of Series D venture funding in a deal led by Premji Invest on September 4, 2025. Baillie Gifford, Socium Ventures, IA Ventures, Lux Capital, FPV Ventures, Level Ventures, Dimension, Kinnevik, Henry Kravis, Lingotto, and Peakline Partners also participated in the round. The company is a developer of a drug analysis platform designed to capitalize on the chemical diversity and evolutionary significance of natural samples.
Galvanize Therapeutics: The company raised $100 million of Series C venture funding in a deal led by Sofinnova Partners on September 3, 2025. Intuitive Surgical, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Apple Tree Partners (ATP), Norwest, Fidelity Management & Research Company, T. Rowe Price Group, Janus Henderson Investors, and Longaeva Partners also participated in the round. The company is a developer of a biomedical platform that develops energy-based medical devices, specifically Pulsed Electric Field technology, to target and treat diseases like solid tumors and chronic bronchitis.
CHARM Therapeutics: The company raised $80 million of Series B venture funding in a deal led by New Enterprise Associates and SR One Capital Management on September 2, 2025. Nvidia, OrbiMed, Khosla Ventures, and F-Prime Capital also participated in the round. The company is a developer of a deep learning platform intended to deliver medicines for patients with cancer and other diseases.
Mercy BioAnalytics: The company raised $59 million of Series B venture funding in a deal led by Sozo Ventures and Novalis LifeSciences on September 3, 2025. Labcorp Venture Fund, Bruker, BrightEdge, Hologic, iSelect Fund, Avestria Ventures, Perceptive Advisors, Portfolia and Mindshift Capital also participated in the round. The company is a developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer.
Avenzo Therapeutics: The company raised $47.2 million of venture funding from undisclosed investors on September 4, 2025. The company is an operator of a clinical-stage oncology platform intended to develop novel treatments for underserved cancers.
Rapafusyn Pharmaceuticals: The company raised $44 million of Series A venture funding in a deal led by 3E Bioventures and Proxima Ventures on September 4, 2025. Yonjin Venture, Lapam Capital, and BioTrack Capital also participated in the round. The company is a developer of non-degrading molecular glues intended to target intracellular and transmembrane proteins considered difficult to drug.
Cresilon: The company raised $41.9 million of Series A venture funding from Catalio Capital Management and William Paseman on September 4, 2025. The company is a developer of hemostatic products designed to support natural clotting and promote wound healing.
Congruence Therapeutics: The company raised $32 million of venture funding from Driehaus Capital Management, BDC Capital and Investissement Quebec on September 4, 2025. OrbiMed, Amplitude Ventures, Lumira Ventures, Fonds de solidarité FTQ Investissements croissance II, Alexandria Real Estate Equities and SilverArc Capital Management also participated in the round. The company is an operator of a computationally-driven biotechnology company intended to discover novel drugs.
Boomerang Medical: The company raised $20 million of Series B venture funding in a deal led by Arboretum Ventures and Hatteras Venture Partners on September 4, 2025, putting the company’s pre-money valuation at $55 million. The company is a developer of bioelectronic medicine technology designed to advance the treatment of autoimmune diseases.
QurAlis: The company raised $20 million of venture funding in the form of convertible debt and promissory notes from undisclosed investors on September 4, 2025. The company is a developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets.
Bright Uro: The company raised $15 million of Series B venture funding from undisclosed investors on September 4, 2025, putting the company’s pre-money valuation at $77 million. The company is a developer of a wireless, catheter-free, urodynamic monitoring system designed to improve the diagnosis and management of lower urinary tract symptoms.
Reveal HealthTech: The company raised $9.85 million of Series A venture funding in a deal led by Leo Capital on September 03, 2025, putting the company’s pre-money valuation at $15.2 million. Sanos Capital and other undisclosed investors also participated in the round. The company is a developer of a healthcare technology platform designed to provide cross-functional technology services to healthcare companies.
Leadoptik: The company raised $4.6 million of Series A venture funding from SCP Ventures, and other undisclosed investors on September 2, 2025, putting the company’s pre-money valuation at $16.7 million. The company is a developer of a miniature imaging technology intended for minimally invasive procedures.
Burl Concepts: The company raised $4.2 million of venture funding from undisclosed investors on September 2, 2025. The company is a developer of portable ultrasound devices designed to offer pre-hospital stroke detection and medical applications.
Alixia: The company raised an undisclosed amount of venture funding from ZAKA VC in September 2025. The company is a developer of mitochondria-targeting therapeutics designed for drug discovery.
AltaThera Pharmaceuticals: The company received an undisclosed amount of development capital in September 2025. The company is a developer of specialty pharmaceuticals intended to serve pediatric cardiac and adult atrial fibrillation patients.
Atom Limbs: The company raised an undisclosed amount of venture funding from rpv in September 2025. The company is a developer of mind-controlled bionic arms designed to help under-elbow amputees regain mobility.
EigenBio: The company is in the process of raising venture funding on September 1, 2025. The company is a developer of an AI-powered cfRNA monitoring platform designed to enable early-stage disease detection and preventative health.
HAI Solutions: The company raised Series A venture funding on September 1, 2025. The company is a developer of a fluid therapy device designed to protect patients from accidental or negligent disconnection of intravenous medications.
Intactis Bio: The company raised an undisclosed amount of venture funding from rpv in September 2025. The company is a developer of tissue culture equipment intended to revolutionize biocomputation and regenerative medicine.
Moab Therapeutics: The company raised an undisclosed amount of venture funding from SciFounders in September 2025. The company is a developer of modular therapeutic agents designed for targeted biological intervention.
PriveBio: The company raised an undisclosed amount of venture funding from LifeSpan Vision Ventures in September 2025. The company is an operator of a precision medicine biotech business focused on developing first-in-class therapeutics for metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases.
XIFIN: The company received an undisclosed amount of development capital from Avista Healthcare Partners and The Goldman Sachs Group on September 3, 2025. The company is a developer of cloud-based software designed to optimize the economics of healthcare for diagnostic service providers.
|
